Goldman Sachs
IMVT icon

Goldman Sachs’s Immunovant IMVT Stock Holding History

Goldman Sachs’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5M Sell
1,751,183
-33,924
-2% -$1.03M 0.01% 1549
2026
Q1 		$44.3M Buy
1,785,107
+489,099
+38% +$12.7M 0.01% 1679
2025
Q4 		$32.9M Sell
1,296,008
-186,531
-13% -$4.16M ﹤0.01% 1872
2025
Q3 		$23.9M Buy
1,482,539
+287,023
+24% +$4.65M ﹤0.01% 2095
2025
Q2 		$19.1M Buy
1,195,516
+187,816
+19% +$2.84M ﹤0.01% 2172
2025
Q1 		$17.2M Buy
1,007,700
+329,354
+49% +$6.89M ﹤0.01% 2164
2024
Q4 		$16.8M Buy
678,346
+156,673
+30% +$4.44M ﹤0.01% 2307
2024
Q3 		$14.9M Buy
521,673
+109,755
+27% +$3.24M ﹤0.01% 2329
2024
Q2 		$10.9M Buy
411,918
+62,741
+18% +$1.78M ﹤0.01% 2430
2024
Q1 		$11.3M Sell
349,177
-108,954
-24% -$3.97M ﹤0.01% 2362
2023
Q4 		$19.3M Sell
458,131
-52,309
-10% -$1.92M ﹤0.01% 1931
2023
Q3 		$19.6M Buy
510,440
+185,194
+57% +$4.19M ﹤0.01% 1820
2023
Q2 		$6.17M Sell
325,246
-115,612
-26% -$2.16M ﹤0.01% 2917
2023
Q1 		$6.84M Buy
440,858
+69,610
+19% +$1.21M ﹤0.01% 2766
2022
Q4 		$6.59M Buy
371,248
+300,179
+422% +$3.78M ﹤0.01% 2941
2022
Q3 		$396K Sell
71,069
-173,883
-71% -$850K ﹤0.01% 5129
2022
Q2 		$955K Sell
244,952
-110,742
-31% -$478K ﹤0.01% 4644
2022
Q1 		$1.96M Buy
355,694
+61,845
+21% +$385K ﹤0.01% 4277
2021
Q4 		$2.5M Sell
293,849
-165,124
-36% -$1.36M ﹤0.01% 4059
2021
Q3 		$3.99M Buy
458,973
+253,239
+123% +$2.28M ﹤0.01% 3547
2021
Q2 		$2.17M Sell
205,734
-840,647
-80% -$11.7M ﹤0.01% 4128
2021
Q1 		$16.8M Buy
1,046,381
+259,626
+33% +$6.85M ﹤0.01% 2077
2020
Q4 		$36.3M Buy
786,755
+663,454
+538% +$30.7M 0.01% 1376
2020
Q3 		$4.34M Sell
123,301
-27,236
-18% -$819K ﹤0.01% 3022
2020
Q2 		$3.67M Buy
150,537
+76,695
+104% +$1.64M ﹤0.01% 3019
2020
Q1 		$1.15M Buy
+73,842
New +$1.11M ﹤0.01% 3659

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's IMVT Position: Q2 2026 in Review

Goldman Sachs reduced its Immunovant (IMVT) stake by 1.9% in Q2 2026, selling an estimated $1.03M and leaving 1,751,183 shares worth $67.5M. The position accounts for 0.01% of the portfolio, ranked #1549.

Goldman Sachs first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Goldman Sachs held 1,751,183 shares of Immunovant worth $67.5M as of Q2 2026.
  • Goldman Sachs sold 33,924 Immunovant shares in Q2 2026, an estimated $1.03M.
  • Immunovant made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1549 holding.
  • Goldman Sachs first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.